Liquid biopsy tests provide access to tumor DNA in a minimally invasive way, offering great potential in oncology applications, including precision medicine, early cancer diagnosis and disease’s follow-up and monitoring. At Aniling, we have developed a new product, GEUS-LB, targeting …
Aniling owns the GEUS technology, which unifies genetic and epigenetic sequencing and provides end-to-end solutions for the right treatment decisions in oncology. Based on GEUS, Aniling is developing a set of products for cancer diagnostic.
The first Aniling product is the most comprehensive Chronic Lymphocytic Leukemia Next Generation Sequencing diagnostics panel. The GEUS-CLL delivers accurate staging and treatment decisions. Aniling S.L. provides the GEUS-CLL diagnostic test as a service to other laboratories and hospitals.
Thanks to the brilliant Aniling teamwork and the invaluable guidance of Ambit BST, we are happy to announce that Aniling has succeeded in the two stages of audits to achieve the ISO 13485:2016. It has been …